Pfizer Inc PFE 企業情報

Pfizer Inc. (PFE) Fundamentals


Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.

SHARE INFORMATION
Market Cap	US$ 244,684,380,668
Shares Outstanding	5,613,314,537
Float	5,612,245,195
Percent Float	99.98%
Short Interest	0.00
Short Percent Float	0.0%
Short Interest Ratio	0.00
Short Interest Date	-
Latest Fiscal Dividend Per Share	US$ 1.60
Latest Fiscal Revenue	US$ 100,331,000,000
Latest Fiscal EPS	US$ 5.48
Latest Fiscal Date	2022-12-31

DIVIDENDS
Dividend (3 Years)	US$ 3.48
Dividend (5 Years)	US$ 4.62
Ex Dividend Date	2023-01-26
Dividend Rate	US$ 1.64
Dividend Yield	3.76%
Payment Cash	Cash

HOLDERS
Institutions	4,808
Institutional Holdings Date	2023-01-31
Institutional Bought Previous 3 Months	144,205,213
Institutional Holdings Percent	128.1%
Institutional Sold Previous 3 Months	193,220,886
Insider Holdings Date	2023-01-31
Insider Bought Previous 3 Months	406,805
Insider Holdings Percent	0.3
Insider Sold Previous 3 Months	883,569
Insider Shares Owned	15,614,446

TRADING INFO
52 Week High	US$ 56.32
52 Week Low	US$ 41.45
52 Week High Change	US$ -15.29
21 Day Moving Average	US$ 45.0168
21 Day Extended Moving Average	US$ 45.4257
50 Day Moving Average	US$ 48.3085
50 Day Extended Moving Average	US$ 47.0349
200 Day Moving Average	US$ 47.7013
200 Day Extended Moving Average	US$ 48.0652
10 Day Average Volume	28,145,642
20 Day Average Volume	26,442,414
30 Day Average Volume	23,328,531
50 Day Average Volume	23,000,185
Alpha	0.005107
Beta	0.6285
Standard Deviation	0.078827
R2	0.185484
7 Day Price Change	US$ -0.57
7 Day Percent Change	-1.29%
21 Day Price Change	US$ -2.07
21 Day Percent Change	-4.54%
30 Day Price Change	US$ -6.87
30 Day Percent Change	-13.61%
Month to Date Price Change	US$ -0.57
Month to Date Percent Change	-1.29%
Quarter to Date Price Change	US$ -7.18
Quarter to Date Percent Change	-14.15%
180 Day Price Change	US$ -4.82
180 Day Percent Change	-9.95%
200 Day Price Change	US$ -6.36
200 Day Percent Change	-12.72%
Year to Date Price Change	US$ -7.18
Year to Date Percent Change	-14.15%

Pfizer Inc. (PFE) Key Ratios

PROFITABILITY
EBIT Margin	34.6%
EBITDA Margin	39.5%
Pre-Tax Profit Margin	12.0%
Profit Margin Count	31.3%
Gross Margin	65.8%
Profit Margin TOT	31.3%

INCOME STATEMENTS
Revenue	US$ 100,331,000,000
Revenue Per Share	US$ 17.8738
Revenue (3 Years)	US$ 30.33
Revenue (5 Years)	US$ 12.97

FINANCIAL STRENGTH
Price to Tangible Book	16.50
Total Debt To Equity	0.40
Int Coverage	29.10
Current Ratio	1.60
Leverage Ratio	2.20
Quick Ratio	1.20
Long Term Debt To Capital	0.25

VALUATION MEASURES
PE Ratio	8.00
Enterprise Value	US$ 245,192,644,139
Price to Sales	2.4388
Price to Free Cash	44.80
PE High Last 5 Years	36.10
Price To Book	2.70
Price To Cash Flow	9.40
PE Low Last 5 Years	8.90
Price to Tangible Book	16.50

MANAGEMENT EFFECTIVENESS
Receivables Turnover	3.40
Invoice Turnover	7.60
Assets Turnover	0.30
Return Assets	17.29
Return on Equity	40.64
Return on Capital	25.39

Pfizer Inc. (PFE) Profile

PROFILE INFO
Issue Type	CS
SEC Type	EQS
Auditor	KPMG LLP
CEO	Albert Bourla
Emplyoees	79000
Last Audit	UE
CIK	0000078003
Industry	Drug Manufacturers
Sector	Healthcare
NAICS	Pharmaceutical Preparation Manufacturing(325412)

CONTACT INFO
Address	235 East 42nd Street New York, NY 10017
Website	https://www.pfizer.com
Facsimile	-
Telephone	+1 212 733-2323
Email	-